These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25758865)

  • 1. The effect of gum chewing on blood GLP-1 concentration in fasted, healthy, non-obese men.
    Xu J; Xiao X; Li Y; Zheng J; Li W; Zhang Q; Wang Z
    Endocrine; 2015 Sep; 50(1):93-8. PubMed ID: 25758865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects.
    Morínigo R; Moizé V; Musri M; Lacy AM; Navarro S; Marín JL; Delgado S; Casamitjana R; Vidal J
    J Clin Endocrinol Metab; 2006 May; 91(5):1735-40. PubMed ID: 16478824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of thirty-times chewing per bite on secretion of glucagon-like peptide-1 in healthy volunteers and type 2 diabetic patients.
    Sonoki K; Iwase M; Takata Y; Nakamoto T; Masaki C; Hosokawa R; Murakami S; Chiwata K; Inoue H
    Endocr J; 2013; 60(3):311-9. PubMed ID: 23138354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral processing effort, appetite and acute energy intake in lean and obese adults.
    Mattes RD; Considine RV
    Physiol Behav; 2013 Aug; 120():173-81. PubMed ID: 23954409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery.
    Werling M; Vincent RP; Cross GF; Marschall HU; Fändriks L; Lönroth H; Taylor DR; Alaghband-Zadeh J; Olbers T; Le Roux CW
    Scand J Gastroenterol; 2013 Nov; 48(11):1257-64. PubMed ID: 24044585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous amylin and glucagon-like peptide-1 concentrations are not associated with gastric emptying in critical illness.
    Summers MJ; DI Bartolomeo AE; Zaknic AV; Chapman MJ; Nguyen NQ; Zacharakis B; Rayner CK; Horowitz M; Deane AM
    Acta Anaesthesiol Scand; 2014 Feb; 58(2):235-42. PubMed ID: 24410108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fourteen weeks of treatment with Viscofiber increased fasting levels of glucagon-like peptide-1 and peptide-YY.
    Greenway F; O'Neil CE; Stewart L; Rood J; Keenan M; Martin R
    J Med Food; 2007 Dec; 10(4):720-4. PubMed ID: 18158848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
    Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.
    Purtell L; Sze L; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    Neuropeptides; 2011 Aug; 45(4):301-7. PubMed ID: 21722955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 as a satiety factor in children with eating disorders.
    Tomasik PJ; Sztefko K; Malek A
    Horm Metab Res; 2002 Feb; 34(2):77-80. PubMed ID: 11972291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.
    Zibar K; Ćuća JK; Blaslov K; Bulum T; Smirčić-Duvnjak L
    Ann Clin Biochem; 2015 Mar; 52(Pt 2):220-5. PubMed ID: 25005458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
    Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
    Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chewing gum for 1 h does not change gastric volume in healthy fasting subjects. A prospective observational study.
    Valencia JA; Cubillos J; Romero D; Amaya W; Moreno J; Ferrer L; Pabón S; Perlas A
    J Clin Anesth; 2019 Sep; 56():100-105. PubMed ID: 30731390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects.
    Fernández-García JC; Murri M; Coin-Aragüez L; Alcaide J; El Bekay R; Tinahones FJ
    Clin Endocrinol (Oxf); 2014 May; 80(5):671-6. PubMed ID: 23573808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects.
    Adam TC; Jocken J; Westerterp-Plantenga MS
    Obes Res; 2005 Apr; 13(4):710-6. PubMed ID: 15897480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.